Erectile Dysfunction News and Research RSS Feed - Erectile Dysfunction News and Research

Erectile Dysfunction (ED) is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. ED affects up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction.
Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs. [More]
Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility. [More]
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. [More]
Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Walking at an easy pace for about three hours every week may be just enough physical activity to help prostate cancer survivors reduce damaging side effects of their treatment, according to a new Northwestern Medicine study. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Viagra and other related drugs are not a universal 'cure-all' for impotence, according to a new study from The University of Manchester and NatCen Social Research. [More]
Study identifies gut immune system as new, effective target for diabetes

Study identifies gut immune system as new, effective target for diabetes

A commonly-used drug to treat inflammatory bowel disease, such as Crohn's disease, has been shown to lower blood sugar levels in obese mice, potentially identifying the gut immune system as a new and effective target in treating diabetes in humans. [More]
Loyola takes holistic approach to help couples manage their sexual health

Loyola takes holistic approach to help couples manage their sexual health

Sexual dysfunction is common among couples, yet it often goes untreated, according to specialists at Loyola University Health System's Sexual Wellness Clinic. [More]
Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint. [More]
Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Doctors strive to make treatment decisions together with their patients - but is the decision really shared? According to adjunct professor Kari Tikkinen, shared decision-making isn't easy, and clinicians need help. The international research group led by Tikkinen has studied the decision aids for treatment choice of localised prostate cancer [More]
Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment as long as possible after the removal of the prostate in order to prevent unwanted side effects. [More]
Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. [More]
Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure. The condition, which affects nearly 6 million Americans and 23 million people worldwide, is marked by progressive weakening and stiffening of the heart muscle and the organ's gradual loss of blood-pumping ability. [More]
Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

New animal studies at Henry Ford Hospital found that sildenafil, a drug commonly used to treat erectile dysfunction, may be effective in relieving painful and potentially life-threatening nerve damage in men with long-term diabetes. [More]

McGill researchers discover that lots of useful medical information getting lost

Lots of potentially useful medical information is getting lost. McGill researchers discovered this when they looked into the lack of reporting of information from "stalled drug" trials in cancer, cardiovascular and neurological diseases. [More]
Men with borderline testosterone levels have higher rates of depression, new research finds

Men with borderline testosterone levels have higher rates of depression, new research finds

Men with borderline testosterone levels have higher rates of depression and depressive symptoms than the general population, new research finds. [More]
Serum testosterone may decline due to decreased sexual activity and desire in older men

Serum testosterone may decline due to decreased sexual activity and desire in older men

In older men, decreased sexual activity and desire, not erectile dysfunction, may cause serum testosterone to decline, a new study from Australia finds. The results will be presented Saturday March 7, at ENDO 2015, the annual meeting of the Endocrine Society, in San Diego. [More]
Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease. [More]
Advertisement
Advertisement